Impact of HIV Infection on the Clinical Presentation and Survival of Non-Hodgkin Lymphoma: A Prospective Observational Study From Botswana.


Journal Article

PURPOSE:Botswana has a high prevalence of HIV infection. Currently, there are few data regarding the sociodemographic factors, clinical characteristics, and outcomes of non-Hodgkin lymphoma (NHL)-an AIDS-defining cancer-in the country. PATIENTS AND METHODS:This study used a prospective cancer registry to identify patients with a new diagnosis of NHL reporting for specialty cancer care at three hospitals in Botswana between October 2010 and August 2016. Treatment patterns and clinical outcomes were analyzed. RESULTS:One hundred four patients with a new diagnosis of NHL were enrolled in this study, 72% of whom had HIV infection. Compared with patients not infected with HIV, patients infected with HIV were younger (median age, 53.9 v 39.1 years; P = .001) and more likely to present with an aggressive subtype of NHL (65.5% v 84.0%; P = .008). All patients infected with HIV received combined antiretroviral therapy throughout the course of the study, and similar chemotherapeutic regimens were recommended for all patients, regardless of subtype or HIV status (six to eight cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone; or cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab). There was no difference in 1-year mortality among patients not infected with HIV and patients infected with HIV (unadjusted analysis, 52.9% v 37.1%; hazard ratio [HR], 0.73; P = .33; adjusted analysis, HR, 0.57; P = .14). However, when compared with a cohort of patients in the United States matched by subtype, stage, age, sex, and race, patients in Botswana fared worse (1-year mortality, 22.8% v 46.3%; HR, 1.89; P = .001). CONCLUSION:Among patients with NHL reporting for specialty cancer care in Botswana, there is no association between HIV status and 1-year survival.

Full Text

Cited Authors

  • Milligan, MG; Bigger, E; Abramson, JS; Sohani, AR; Zola, M; Kayembe, MKA; Medhin, H; Suneja, G; Lockman, S; Chabner, BA; Dryden-Peterson, SL

Published Date

  • September 2018

Published In

Volume / Issue

  • 4 /

Start / End Page

  • 1 - 11

PubMed ID

  • 30241264

Pubmed Central ID

  • 30241264

Electronic International Standard Serial Number (EISSN)

  • 2378-9506

International Standard Serial Number (ISSN)

  • 2378-9506

Digital Object Identifier (DOI)

  • 10.1200/jgo.17.00084


  • eng